opana® er induced thrombotic thrombocytopenic purpura

Clicks: 140
ID: 254073
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #61 of 66 articles by views in Biochemical and biophysical research communications

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Nabil Kotbi, Bernadine Han, Duncan Cheng, Anna E Odom Department of Psychiatry, Weill Cornell Medical College, New York-Presbyterian Hospital, White Plains, NY, USA Abstract: We present the case of a patient who developed thrombotic thrombocytopenic purpura (TTP) following intravenous injection of Opana® ER. TTP reemerged after three months of abstinence with Opana misuse. This case report brings awareness to the possibility of developing TTP in those who misuse Opana, which is a growing concern. Keywords: opioid abuse, opioid dependence, TTP, Opana 
Reference Key
n2015internationalopana® Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Biochemical and biophysical research communications
Year 2015
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.